Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 139,866,224
  • Shares Outstanding, K 2,233,928
  • Annual Sales, $ 42,518 M
  • Annual Income, $ -9,015 M
  • 60-Month Beta 0.64
  • Price/Sales 3.25
  • Price/Cash Flow 5.57
  • Price/Book 3.70
Trade BMY with:

Options Overview

Details
  • Implied Volatility 21.02%
  • Historical Volatility 14.09%
  • IV Percentile 1%
  • IV Rank 0.45%
  • IV High 437.70% on 12/14/20
  • IV Low 19.14% on 09/24/20
  • Put/Call Vol Ratio 0.74
  • Today's Volume 20,024
  • Volume Avg (30-Day) 25,838
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 422,069
  • Open Int (30-Day) 422,199

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate 1.81
  • Number of Estimates 5
  • High Estimate 1.96
  • Low Estimate 1.76
  • Prior Year 1.72
  • Growth Rate Est. (year over year) +5.23%

Price Performance

See More
Period Period Low Period High Performance
1-Month
60.20 +4.00%
on 03/12/21
64.42 -2.80%
on 03/29/21
+2.04 (+3.37%)
since 03/09/21
3-Month
58.63 +6.80%
on 03/04/21
67.16 -6.77%
on 01/19/21
+0.12 (+0.19%)
since 01/08/21
52-Week
54.07 +15.79%
on 06/15/20
67.16 -6.77%
on 01/19/21
+3.70 (+6.28%)
since 04/09/20

Most Recent Stories

More News
Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial

--Opdivo-based therapies have now demonstrated positive results in Phase 3 trials in earlier stages of four different types of cancer: non-small cell lung cancer, esophageal/gastroesophageal junction cancer,...

BMY : 62.61 (+1.13%)
Bristol Myers' (BMY) Opdivo Combo Positive in ESCC Study

Bristol Myers (BMY) announces encouraging data from the late-stage study evaluating Opdivo plus chemotherapy and Opdivo plus Yervoy in ESCC study.

RHHBY : 41.9300 (+1.28%)
MRK : 76.31 (+1.09%)
MRNA : 140.92 (+5.26%)
BMY : 62.61 (+1.13%)
CORRECTING and REPLACING Bristol Myers Squibb Announces Opdivo (nivolumab) plus Chemotherapy and Opdivo plus Yervoy (ipilimumab) Demonstrate Superior Survival Benefit Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal...

--Statistically significant overall survival benefit demonstrated with Opdivo plus chemotherapy and Opdivo plus Yervoy in PD-L1 positive and all-randomized populations in CheckMate -648

BMY : 62.61 (+1.13%)
Novartis (NVS) Teams Up With Artios for Radioligand Therapies

Novartis (NVS) enters a three-year collaboration with Artios to strengthen its radiogland therapies pipeline.

AZN : 49.94 (+0.89%)
RHHBY : 41.9300 (+1.28%)
NVS : 87.55 (+0.64%)
BMY : 62.61 (+1.13%)
Bristol Myers Squibb Announces Opdivo (nivolumab) plus Chemotherapy and Opdivo plus Yervoy (ipilimumab) Demonstrate Superior Survival Benefit Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma

--Statistically significant overall survival benefit demonstrated with Opdivo plus chemotherapy and Opdivo plus Yervoy in PD-L1 positive and all-randomized populations in CheckMate -648

BMY : 62.61 (+1.13%)
BMY vs. ILMN: Which Stock Should Value Investors Buy Now?

BMY vs. ILMN: Which Stock Is the Better Value Option?

BMY : 62.61 (+1.13%)
ILMN : 403.37 (-0.09%)
The Zacks Analyst Blog Highlights: Google, Visa, PayPal, Bristol-Myers Squibb and Target

The Zacks Analyst Blog Highlights: Google, Visa, PayPal, Bristol-Myers Squibb and Target

TGT : 205.36 (+0.93%)
V : 222.52 (+0.82%)
BMY : 62.61 (+1.13%)
GOOGL : 2,270.67 (+0.90%)
PYPL : 266.77 (+0.86%)
PsiOxus Therapeutics Updates Agreement with Bristol Myers Squibb to Advance their Clinical Stage Immuno-Oncology Collaboration

PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an updated agreement to advance its clinical collaboration with Bristol Myers Squibb (NYSE: BMY) to evaluate the safety, tolerability, and preliminary...

BMY : 62.61 (+1.13%)
Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know

Bristol Myers Squibb (BMY) closed at $63.16 in the latest trading session, marking a +0.22% move from the prior day.

BMY : 62.61 (+1.13%)
Top Stock Reports for Alphabet, Visa & PayPal

Top Stock Reports for Alphabet, Visa & PayPal

V : 222.52 (+0.82%)
TGT : 205.36 (+0.93%)
PYPL : 266.77 (+0.86%)
GOOGL : 2,270.67 (+0.90%)
COST : 363.21 (+0.55%)
BMY : 62.61 (+1.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products. It offers products which includes hematology, oncology, cardiovascular and immunology. Bristol-Myers Squibb Company, formerly known as Bristol-Myers Company, is based in...

See More

Key Turning Points

3rd Resistance Point 63.90
2nd Resistance Point 63.27
1st Resistance Point 62.94
Last Price 62.61
1st Support Level 61.98
2nd Support Level 61.35
3rd Support Level 61.02

See More

52-Week High 67.16
Last Price 62.61
Fibonacci 61.8% 62.16
Fibonacci 50% 60.61
Fibonacci 38.2% 59.07
52-Week Low 54.07

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar